title: Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
abstract: BACKGROUND
  Recent epidemiologic studies have identified obesity as a risk factor for benign prostatic hyperplasia (BPH). We examined whether adiponectin, leptin, and C-peptide were associated with incident, symptomatic BPH and whether these factors mediate the relationship between obesity and BPH risk.
  
  
  METHODS
  Data are from Prostate Cancer Prevention Trial placebo arm participants who were free of BPH at baseline. Incident BPH (n = 698) was defined as treatment, two International Prostate Symptom Score (IPSS) values > 14, or an increase of >or=5 in IPSS from baseline documented on at least two occasions plus at least one score >or=12. Controls (n = 709) were selected from men reporting no BPH treatment or IPSS > 7 during the 7-year trial. Baseline serum was analyzed for adiponectin, C-peptide, and leptin concentrations.
  
  
  RESULTS
  Neither C-peptide nor leptin was associated with BPH risk. The odds ratio [95% CI] contrasting highest to lowest quartiles of adiponectin was 0.65[0.47, 0.87] P(trend) = 0.004. Findings differed between levels of physical activity: there was a strong inverse association between adiponectin and BPH among moderately/very active men OR = 0.43 [0.29, 0.63], and no association among sedentary/minimally active men OR = 0.92 [0.65, 1.30] P(interaction) = 0.005. Adiponectin concentrations explained only a moderate amount of the relationship between obesity and BPH risk.
  
  
  CONCLUSIONS
  High adiponectin concentrations were associated with reduced risk of incident, symptomatic BPH. This association was limited to moderately/very active men; suggesting the relationship between obesity and BPH involves a complex interaction between factors affecting glucose uptake and insulin sensitivity. However, adiponectin is likely not the only mechanism through which obesity affects BPH risk.
authors.affiliation: Fred Hutchinson Cancer Research Center, Cancer Prevention Program, Seattle, Washington 98109-1024, USA. jschenk@fhcrc.org
authors.forename: Jeannette M
authors.initials: JM
authors.lastname: Schenk
authors.forename: Alan R
authors.initials: AR
authors.lastname: Kristal
authors.forename: Marian L
authors.initials: ML
authors.lastname: Neuhouser
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Tangen
authors.forename: Emily
authors.initials: E
authors.lastname: White
authors.forename: Daniel W
authors.initials: DW
authors.lastname: Lin
authors.forename: Ian M
authors.initials: IM
authors.lastname: Thompson
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000368:Aged; D002096:C-Peptide / Q000097:blood*; D016022:Case-Control Studies; D018450:Disease Progression; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D020738:Leptin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000453:epidemiology; D011470:Prostatic Hyperplasia / Q000097:blood* / Q000150:complications / Q000453:epidemiology; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D012307:Risk Factors; D014861:Washington / Q000453:epidemiology
chemical_list: D052242:Adiponectin; D002096:C-Peptide; D020738:Leptin